Delcath Systems Inc (DCTH)

[ash111]

Almost 50% of total O/S in volume.on zero posts.liver cancer, only 6m mc is a joke.they did financing too.they did it after years. No doubt, risk/ reward ratio very impresive.solid Catalysts ahead.on good data this can shoot up over 20 easily imo. Remember Aqxp? When i posted my DD it was an unknown company trading under a buck and ran to almost 40 in a couple of days after a good data- history not always points of the future as you can see and investors always looking forward.
did some DD read:

$29.2 million restricted cash(see presentation below) .p2, p3 company trading on only $6m cap.

also have noticed they might present some data later this year(see at the bottom)

latest presentation: June 2016:
http://delcath.com/wp-content/uploads/2016/07/DCTH_ASM_July2016-FINAL.pdf

NEW YORK, July 6, 2016 /PRNewswire:
"The progression free and overall survival benefits observed in this study are dramatic, especially given the limited treatment options for patients suffering with these life-threatening cancers. Importantly, these supportive data provide us with considerable confidence that similar results may be formally validated by our FOCUS Phase 3 Trial in hepatic dominant ocular melanoma that is currently underway in the U.S. and Europe to secure marketing authorization in the U.S.," said Jennifer K. Simpson, Ph.D., MSN, CRNP, President and CEO of Delcath Systems. "The quality and pace of global research being presented and published continues to strongly support CHEMOSAT as a therapy for metastatic liver cancer. We look forward to building on this momentum to further advance the commercial and clinical adoption of CHEMOSAT in Europe, the U.S. and around the world."
http://delcath.com/investors-news/

NEW YORK, July 7, 2016 /PRNewswire:
"We look forward to results from additional studies being accepted for publication and presentation at a number of the major medical conferences later this year."
http://delcath.com/investors-news/

Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 2016
NEW YORK, July 18, 2016 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that abstracts from two studies conducted in Germany of use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with liver metastases, have been accepted for presentation as posters at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) annual meeting. The abstracts are:

Percutaneous Isolated Hepatic Perfusion (Chemosaturation) In Patients With Primary Or Secondary Liver Tumours: Experience In 20 Patients, by S. Marquardt, et al, of Hanover Medical School in Hanover, Germany.

Secondary Resectability Of Ocular Melanoma Liver Metastases Following Percutaneous Hepatic Perfusion by M. Zeile, and A. Stang, et al of the Asklepios Barmbek Clinic in Hamburg, Germany.

The CIRSE conference will be held in Barcelona, Spain at the Centre de Convencions Internacional de Barcelona from September 10-14, 2016. Additional information for the CIRSE Scientific Program is available here.